Watertown, Massachusetts-based Matchpoint Therapeutics raised USD 150 million in a Series B financing co-led by Nextech Invest and Norwest, with proceeds supporting advancement of lead program MPT-062 through clinical proof of concept and further development of its covalent small-molecule pipeline.
New investors Invus, BB Biotech, T1D Fund, and BOLD Longevity Growth joined existing backers including Access Biotechnology, Atlas Venture, Sanofi Ventures, and Digitalis Ventures. Kanishka Pothula of Nextech Invest and Brian Matesic of Norwest will join Matchpoint’s board.
MPT-062 is an oral T-cell modulator designed to suppress disease-causing T-cell overactivation in autoimmune and inflammatory disorders. Matchpoint expects clinical development to begin in 2027 but has not disclosed the molecular target or initial indication.
The company develops covalent small molecules using its Advanced Covalent Exploration (ACE) platform, which is designed to identify druggable binding sites on biologically validated proteins that have been difficult to address with conventional small molecules. In 2025, Matchpoint entered an exclusive option and license agreement with Novartis covering oral covalent inhibitors against an undisclosed transcription factor implicated in inflammatory diseases. The deal included up to USD 60 million in upfront payment and research funding and up to USD 1 billion in potential total payments.